Filing Analysis
Securities Offering
Filed Apr 02, 2026
MEDIUM
Palisade Bio entered into a strategic partnership with Iterative Health to expedite Phase 2 clinical trial enrollment for PALI-2108 and simultaneously secured a $3.0 million private placement investment from an affiliate of the partner.
Red Flags
- The transaction involves a private placement (PIPE), which results in immediate dilution of existing shareholders.
Key Facts
- Entered into a Master Services Agreement (MSA) with Iterative Scopes, Inc. (d/b/a Iterative Health) on March 30, 2026.
- The MSA is designed to assist with Study Enrollment for a Phase 2 study of PALI-2108 for moderate to severe Ulcerative Colitis.
- Issued and sold 1,536,885 shares of common stock to an affiliate of Iterative Health on March 27, 2026.
- The total purchase price was $3.0 million, representing $1.952 per share.
- The share price was calculated based on the average closing price for the five trading days prior to the Closing Date.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.